
Bausch Health (BHC) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
2.5B
Gross Profit
1.8B
69.80%
Operating Income
457.0M
18.06%
Net Income
128.0M
5.06%
Balance Sheet Metrics
Total Assets
26.4B
Total Liabilities
26.7B
Shareholders Equity
-240.0M
Cash Flow Metrics
Operating Cash Flow
236.0M
Free Cash Flow
87.0M
Revenue & Profitability Trend
Bausch Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 9.6B | 8.8B | 8.1B | 8.4B | 8.0B |
Cost of Goods Sold | 2.8B | 2.6B | 2.4B | 2.4B | 2.2B |
Gross Profit | 6.8B | 6.2B | 5.8B | 6.0B | 5.8B |
Gross Margin % | 71.1% | 70.8% | 70.9% | 71.6% | 72.0% |
Operating Expenses | |||||
Research & Development | 616.0M | 604.0M | 530.0M | 473.0M | 484.0M |
Selling, General & Administrative | 3.3B | 2.9B | 2.6B | 2.6B | 2.4B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 3.9B | 3.5B | 3.2B | 3.1B | 2.9B |
Operating Income | 1.9B | 1.6B | 1.4B | 1.6B | 1.3B |
Operating Margin % | 19.3% | 18.3% | 17.1% | 18.6% | 16.0% |
Non-Operating Items | |||||
Interest Income | 33.0M | 26.0M | 14.0M | 7.0M | 13.0M |
Interest Expense | 1.4B | 1.3B | 1.5B | 1.4B | 1.5B |
Other Non-Operating Income | -332.0M | -688.0M | -69.0M | -1.2B | -695.0M |
Pre-tax Income | 167.0M | -390.0M | -129.0M | -1.0B | -934.0M |
Income Tax | 239.0M | 221.0M | 83.0M | -87.0M | -375.0M |
Effective Tax Rate % | 143.1% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -72.0M | -611.0M | -212.0M | -937.0M | -559.0M |
Net Margin % | -0.7% | -7.0% | -2.6% | -11.1% | -7.0% |
Key Metrics | |||||
EBITDA | 3.2B | 2.9B | 2.8B | 3.1B | 3.1B |
EPS (Basic) | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 |
EPS (Diluted) | $-0.13 | $-1.62 | $-0.62 | $-2.64 | $-1.58 |
Basic Shares Outstanding | 353846154 | 365432099 | 362903226 | 359405748 | 355000000 |
Diluted Shares Outstanding | 353846154 | 365432099 | 362903226 | 359405748 | 355000000 |
Income Statement Trend
Bausch Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.2B | 947.0M | 564.0M | 582.0M | 605.0M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 2.1B | 2.0B | 1.8B | 1.8B | 1.6B |
Inventory | 1.6B | 1.5B | 1.1B | 993.0M | 1.1B |
Other Current Assets | 838.0M | 1.1B | 776.0M | 720.0M | 855.0M |
Total Current Assets | 5.8B | 5.6B | 4.2B | 5.6B | 5.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 97.0M | 84.0M | 78.0M | 73.0M | 65.0M |
Goodwill | 27.7B | 28.8B | 28.9B | 31.9B | 34.5B |
Intangible Assets | 5.6B | 6.5B | 5.8B | 6.9B | 8.4B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 2.3B | 2.4B | 2.5B | 2.6B | 2.8B |
Total Non-Current Assets | 20.7B | 21.8B | 21.4B | 23.6B | 25.9B |
Total Assets | 26.5B | 27.4B | 25.7B | 29.2B | 31.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 656.0M | 719.0M | 521.0M | 407.0M | 337.0M |
Short-term Debt | 2.7B | 450.0M | 432.0M | - | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 1.0B | 1.0B | 1.0B | 2.6B | 2.4B |
Total Current Liabilities | 6.8B | 4.3B | 3.9B | 5.2B | 4.9B |
Non-Current Liabilities | |||||
Long-term Debt | 18.9B | 21.9B | 20.3B | 22.7B | 23.9B |
Deferred Tax Liabilities | 128.0M | 163.0M | 202.0M | 529.0M | 528.0M |
Other Non-Current Liabilities | 1.0B | 1.0B | 949.0M | 855.0M | 1.2B |
Total Non-Current Liabilities | 20.1B | 23.1B | 21.5B | 24.0B | 25.7B |
Total Liabilities | 26.8B | 27.4B | 25.4B | 29.2B | 30.6B |
Equity | |||||
Common Stock | 10.5B | 10.4B | 10.4B | 10.3B | 10.2B |
Retained Earnings | -9.8B | -9.8B | -9.2B | -9.0B | -8.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -322.0M | -82.0M | 260.0M | -34.0M | 605.0M |
Key Metrics | |||||
Total Debt | 21.6B | 22.4B | 20.8B | 22.7B | 23.9B |
Working Capital | -978.0M | 1.3B | 306.0M | 409.0M | 429.0M |
Balance Sheet Composition
Bausch Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -72.0M | -611.0M | -212.0M | -937.0M | -559.0M |
Depreciation & Amortization | 1.3B | 1.3B | 1.4B | 1.6B | 1.8B |
Stock-Based Compensation | 150.0M | 132.0M | 126.0M | 128.0M | 105.0M |
Working Capital Changes | -126.0M | -359.0M | -330.0M | -124.0M | -378.0M |
Operating Cash Flow | 1.4B | 628.0M | -669.0M | 662.0M | 900.0M |
Investing Activities | |||||
Capital Expenditures | -337.0M | -215.0M | -218.0M | -269.0M | -302.0M |
Acquisitions | -136.0M | -1.9B | -45.0M | 0 | 0 |
Investment Purchases | -12.0M | -27.0M | -17.0M | -19.0M | -4.0M |
Investment Sales | 14.0M | 26.0M | 22.0M | 15.0M | 8.0M |
Investing Cash Flow | -464.0M | -2.1B | -253.0M | 396.0M | -277.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 661.0M | 3.3B | 6.8B | 2.1B | 3.5B |
Debt Repayment | -1.5B | -1.7B | -7.8B | -3.4B | -5.6B |
Financing Cash Flow | -868.0M | 1.5B | -474.0M | -1.5B | -2.3B |
Free Cash Flow | 1.3B | 760.0M | -996.0M | 1.1B | 802.0M |
Net Change in Cash | 84.0M | 2.0M | -1.4B | -455.0M | -1.7B |
Cash Flow Trend
Bausch Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.85
Forward P/E
1.70
Price to Sales
0.28
PEG Ratio
1.70
Profitability Ratios
Profit Margin
0.99%
Operating Margin
18.02%
Return on Equity
14.29%
Return on Assets
4.35%
Financial Health
Current Ratio
1.31
Debt to Equity
14,787.76
Beta
0.41
Per Share Data
EPS (TTM)
$0.26
Book Value per Share
$-2.07
Revenue per Share
$26.68
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
bhc | 2.8B | 28.85 | - | 14.29% | 0.99% | 14,787.76 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.4B | 21.51 | 5.46 | 9.38% | 13.81% | 53.41 |
Elanco Animal Health | 8.7B | 19.88 | 1.28 | 6.83% | 9.68% | 62.13 |
Regencell Bioscience | 6.1B | - | 878.57 | -47.77% | 0.00% | 0.01 |
Alkermes plc | 4.8B | 14.04 | 2.95 | 23.94% | 23.15% | 4.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.